Clinical Research Directory
Browse clinical research sites, groups, and studies.
Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis
Sponsor: Shandong Cancer Hospital and Institute
Summary
Olanzapine is an effective antiemetic agent for preventing highly emetogenic regimens-induced nausea and vomiting (HER-INV) in patients receiving highly emetogenic regimens (HER). The optimal dose remains debated, with the standard 10 mg dose often causing significant daytime sedation. Recent evidence suggests that lower doses (2.5 mg and 5 mg) may offer comparable efficacy with improved tolerability. However, no head-to-head randomized controlled trials (RCTs) directly compare all three doses.
Official title: Olanzapine 2.5 mg Versus 5 mg Versus 10 mg in Highly Emetogenic Regimens: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
2000
Start Date
2026-01-18
Completion Date
2026-03-30
Last Updated
2026-02-11
Healthy Volunteers
No
Interventions
Olanzapine (dose comparison: 2.5 mg, 5 mg, 10 mg)
Olanzapine (dose: 2.5 mg) vs. olanzapine (dose: 5 mg) vs. olanzapine (dose: 10 mg)
Locations (1)
Department of Medical Oncology
Jinan, Shandong, China